SB
SPRO icon

Samsara BioCapital’s Spero Therapeutics SPRO Stock Holding History

Samsara BioCapital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-160,000
Closed -$1.79M – 44
2020
Q3 		$1.79M Buy
+160,000
New +$1.89M 0.5% 30

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Samsara BioCapital's SPRO Position: Q4 2020 in Review

Samsara BioCapital sold out of Spero Therapeutics (SPRO) in Q4 2020, closing a stake of 160,000 shares — an estimated $1.79M sold.

Samsara BioCapital first reported a position in SPRO in Q3 2020 and held it in 1 quarter. The position peaked at $1.79M in Q3 2020. 89 funds tracked by Wall St. Rank hold SPRO as of Q4 2020.

  • Samsara BioCapital reported no remaining Spero Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Samsara BioCapital sold 160,000 Spero Therapeutics shares in Q4 2020, an estimated $1.79M.
  • Samsara BioCapital first reported a position in Spero Therapeutics in Q3 2020 and held it in 1 quarter.
  • Samsara BioCapital's Spero Therapeutics position peaked at $1.79M in Q3 2020.
  • 89 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2020.

Based on Samsara BioCapital's 13F filing for Q4 2020, filed 17 Feb 2021.